Search - tctmd.com

Displaying 181 - 200 of 480

Sort: Relevancy | Date

Presentation TCT 2018

Shared Decision-making in NVAF: The Patients Perspective

Presenter: James B. Hermiller Jr, David Hildick-Smith, Megan Coylewright

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Presenter: James B. Hermiller Jr, David Hildick-Smith, David R. Holmes Jr.

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

Presentation TCT 2018

Stroke Etiology, LAA Closure, and the Therapeutic Landscape: A Neurologists Perspective

Presenter: James B. Hermiller Jr, David Hildick-Smith, David E. Thaler

September 24, 2018

Presentation TCT 2018

A Patient With Atrial Fibrillation, Cryptogenic Stroke, and PFO: Watchman Despite OAC?

Presenter: Zahid Amin, Robert J. Sommer, Peter C. Block, John P. Breinholt, Craig E Fleishman, Jan Kovac, Harsimran Sachdeva Singh, Christian Spies

September 24, 2018

Presentation TCT 2018

OAC-ALONE: A Randomized Trial of Oral Anticoagulation With vs Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation Beyond One Year After Coronary Stent Implantation

Presenter: Gregg W. Stone, Yukiko Nakano

September 24, 2018

Presentation TCT 2018

Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

Presenter: Davide Capodanno, Giulio Stefanini, Robert A. Byrne

September 23, 2018

Presentation TCT 2018

US and ESC Guidelines and Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI

Presenter: Davide Capodanno, Giulio Stefanini, Dominick J. Angiolillo

September 23, 2018

Presentation TCT 2018

TAVI/LAAO: A Randomized Trial of Left Atrial Appendage Occlusion vs Standard Medical Therapy in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

Presenter: Horst Sievert, Brian K. Whisenant, Fabian Nietlispach

September 23, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Case Introduction: A Patient With Non-Valvular Atrial Fibrillation

Presenter: Martina Kelly Speight, Asma Hussaini, David P. Lee, Elizabeth M. Perpetua

September 21, 2018

Presentation TCT 2018

TAVR in the Patient With Atrial Fibrillation and Contraindications to Chronic Anticoagulation

Presenter: Anibal A. Damonte

September 21, 2018

Presentation TCT 2018

Atrial Fibrillation and ACS/PCI: The End of Triple Therapy?

Presenter: Jeroen J. Bax, Stephan Windecker

September 21, 2018

Presentation The Structural Heart Disease Summit 2018

A Rare Case of Platypnea-Orthodeoxia Syndrome Developing After Atrial Fibrillation Ablation Necessitating Percutaneous Closure of the Septal Puncture Site

Presenter: Horst Sievert, Robert J. Sommer, Nadim Geloo, MD

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Indications and Uncertainties for Atrial Fibrillation Treatment: Risk Scores, Single AF Episode, Post-CABG AF, Valvular vs. Nonvalvular, and More

Presenter: William A. Gray, Gregg W. Stone, Vivek Y. Reddy

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Atrial Fibrillation + PCI: The Myths and Realities of Triple Therapy

Presenter: Anthony N. DeMaria, Vivek Y. Reddy, Ashish Pershad

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Pharmacologic Agents to Prevent Stroke in Nonvalvular Atrial Fibrillation and PFO: Evidence and Real-world Practices

Presenter: Anthony N. DeMaria, Vivek Y. Reddy, Gregg W. Stone

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

An Introduction to the WATCH-TAVR Trial Combining TAVR and LAAC

Presenter: Amar Krishnaswamy

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

European Perspectives and Updates From a Randomized Trial Combining TAVR and LAAC

Presenter: Fabian Nietlispach

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Pharmacotherapy Considerations Trials and Practical Clinical Recommendations

Presenter: George D. Dangas

June 21, 2018

Advertisement

Shared Decision-making in NVAF: The Patients Perspective

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Stroke Etiology, LAA Closure, and the Therapeutic Landscape: A Neurologists Perspective

A Patient With Atrial Fibrillation, Cryptogenic Stroke, and PFO: Watchman Despite OAC?

OAC-ALONE: A Randomized Trial of Oral Anticoagulation With vs Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation Beyond One Year After Coronary Stent Implantation

Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

US and ESC Guidelines and Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI

TAVI/LAAO: A Randomized Trial of Left Atrial Appendage Occlusion vs Standard Medical Therapy in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Case Introduction: A Patient With Non-Valvular Atrial Fibrillation

TAVR in the Patient With Atrial Fibrillation and Contraindications to Chronic Anticoagulation

Atrial Fibrillation and ACS/PCI: The End of Triple Therapy?

A Rare Case of Platypnea-Orthodeoxia Syndrome Developing After Atrial Fibrillation Ablation Necessitating Percutaneous Closure of the Septal Puncture Site

Indications and Uncertainties for Atrial Fibrillation Treatment: Risk Scores, Single AF Episode, Post-CABG AF, Valvular vs. Nonvalvular, and More

Atrial Fibrillation + PCI: The Myths and Realities of Triple Therapy

Pharmacologic Agents to Prevent Stroke in Nonvalvular Atrial Fibrillation and PFO: Evidence and Real-world Practices

An Introduction to the WATCH-TAVR Trial Combining TAVR and LAAC

European Perspectives and Updates From a Randomized Trial Combining TAVR and LAAC

Pharmacotherapy Considerations Trials and Practical Clinical Recommendations

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content